A novel calcimimetic evocalcet for the management of secondary hyperparathyroidism with little effect on the gastrointestinal tract and cyp isozymes in vivo and in vitro

In the treatment of secondary hyperparathyroidism of end-stage chronic kidney disease, vitamin D receptor activation and allosteric modulators of the calcium-sensing receptor - inhibit glandular hyperplasia; reduce parathyroid hormone levels, impact on bone turnover and mineral density. Cinacalcet, an oral calcimimetic agent has been widely used for the management of secondary hyperparathyroidism in chronic kidney disease. Nevertheless, some patients remain refractory to the treatment, as the dose of cinacalcet cannot be sufficiently increased due to gastrointestinal symptoms and it strong inhibits of cytochrome P450 (CYP) 2D6. In order to resolve this issue, was develop a newly synthesized calcimimetic agent, evocalcet (MT-4580/KHK7580). In a rat model of chronic kidney disease induced by 5/6 nephrectomy, and in multicenter, open-label study phase 3, and in clinical practice oral administration of evocalcet efficiently suppressed the secretion of parathyroid hormone. Evocalcet also demonstrated the less induction of emesis and gastro-intestinal effects, and its pharmacological effects were observed at lower doses because of its higher bioavailability than cinacalcet. In addition, evocalcet showed no substantial direct inhibition of any CYP isozymes in in vitro. These findings suggest that evocalcet can be a better alternative to cinacalcet with a wider safety margin.

1. Goodman WG, Quarles LD. Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics. Kidney Int. 2008;74(3):276-288. doi: https://doi.org/10.1038/sj.ki.5002287

2. Tentori F, Blayney MJ, Albert JM, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2008;52(3):519-530. doi: https://doi.org/10.1053/j.ajkd.2008.03.020

3. Taniguchi M, Fukagawa M, Fujii N, et al. Serum phosphate and calcium should be primarily and consistently controlled in prevalent hemodialysis patients. Ther Apher Dial. 2013;17(2):221-228. doi: https://doi.org/10.1111/1744-9987.12030

4. Raggi P, Boulay A, Chasan-Taber S, et al. Cardiac calcification in adult hemodialysis patients. J Am Coll Cardiol. 2002;39(4):695-701. doi: https://doi.org/10.1016/s0735-1097(01)01781-8

5. Tentori F, McCullough K, Kilpatrick RD, et al. High rates of death and hospitalization follow bone fracture among hemodialysis patients. Kidney Int. 2014;85(1):166-173. doi: https://doi.org/10.1038/ki.2013.279

6. Hofer AM, Brown EM. Extracellular calcium sensing and signalling. Nat Rev Mol Cell Biol. 2003;4(7):530-538. doi: https://doi.org/10.1038/nrm1154

7. Lindberg JS. Calcimimetics: a new tool for management of hyperparathyroidism and renal osteodystrophy in patients with chronic kidney disease. Kidney Int Suppl. 2005(95):S33-36. doi: https://doi.org/10.1111/j.1523-1755.2005.09505.x

8. Dorsch O. Use of cinacalcet in a patient on long-term dialysis with end-stage renal failure and refractory secondary hyperparathyroidism. Nephrol Dial Transplant. 2007;22(2):637-640. doi: https://doi.org/10.1093/ndt/gfl547

9. Nemeth EF, Heaton WH, Miller M, et al. Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther. 2004;308(2):627-635. doi: https://doi.org/10.1124/jpet.103.057273

10. Tominaga Y, Kakuta T, Yasunaga C, et al. Evaluation of Parathyroidectomy for Secondary and Tertiary Hyperparathyroidism by the Parathyroid Surgeons’ Society of Japan. Ther Apher Dial. 2016;20(1):6-11. doi: https://doi.org/10.1111/1744-9987.12352

11. Егшатян Л.В. Эффективность терапевтического и хирургического лечения вторичного гиперпаратиреоза у пациентов, получающих заместительную почечную терапию программным гемодиализом: Дис. … канд. мед. наук. — М.; 2012. [Egshatyan LV. Effektivnost’ terapevticheskogo i khirurgicheskogo lecheniya vtorichnogo giperparatireoza u patsientov, poluchayushchikh zamestitel’nuyu pochechnuyu terapiyu programmnym gemodializom. [dissertation] Moscow; 2012. (In Russ.)]

12. Nakashima D, Takama H, Ogasawara Y, et al. Effect of cinacalcet hydrochloride, a new calcimimetic agent, on the pharmacokinetics of dextromethorphan: in vitro and clinical studies. J Clin Pharmacol. 2007;47(10):1311-1319. doi: https://doi.org/10.1177/0091270007304103

13. Kiefer L, Leiris S, Dodd RH. Novel calcium sensing receptor ligands: a patent survey. Expert Opin Ther Pat. 2011;21(5):681-698. doi: https://doi.org/10.1517/13543776.2011.568479

14. Walter S, Baruch A, Dong J, et al. Pharmacology of AMG 416 (Velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patients. J Pharmacol Exp Ther. 2013;346(2):229-240. doi: /https://doi.org/10.1124/jpet.113.204834

15. Block GA, Bushinsky DA, Cheng S, et al. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial. JAMA. 2017;317(2):156-164. doi: https://doi.org/10.1001/jama.2016.19468

16. Kawata T, Tokunaga S, Murai M, et al. A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro. PLoS One. 2018;13(4):e0195316. doi: https://doi.org/10.1371/journal.pone.0195316

17. Palmer SC, Nistor I, Craig JC, et al. Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials. PLoS Med. 2013;10(4):e1001436. doi: https://doi.org/10.1371/journal.pmed.1001436

18. Fukumoto K, Noguchi T, Toriie S, et al. The mechanism of upper-gastrointestinal complication after taking cinacalcet hydrochloride. J Jpn Soc Dial Ther. 2010;43:309-315.

19. Sassi G, Striano B, Merlo UA. A reporting system for the assessment of chemotherapy toxicity. J Oncol Pharm Pract. 2005;11(2):63-67. doi: https://doi.org/10.1191/1078155205jp154oa

20. Boussios S, Pentheroudakis G, Katsanos K, Pavlidis N. Systemic treatment-induced gastrointestinal toxicity: incidence, clinical presentation and management. Ann Gastroenterol. 2012;25(2):106-118.

21. Yokoyama K, Shimazaki R, Fukagawa M, et al. Long-Term Efficacy and Safety of Evocalcet in Japanese Patients with Secondary Hyperparathyroidism Receiving Hemodialysis. Sci Rep. 2019;9(1):6410. doi: https://doi.org/10.1038/s41598-019-42017-z

22. Akizawa T, Shimazaki R, Fukagawa M, Evocalcet Study G. Phase 2b study of evocalcet (KHK7580), a novel calcimimetic, in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: A randomized, double-blind, placebo-controlled, dose-finding study. PLoS One. 2018;13(10):e0204896. doi: https://doi.org/ 10.1371/journal.pone.0204896

23. Tsuruya K, Shimazaki R, Fukagawa M, Akizawa T. Efficacy and safety of evocalcet in Japanese peritoneal dialysis patients. Clin Exp Nephrol. 2019;23(6):739-748. doi: https://doi.org/ 10.1007/s10157-019-01692-y.